🧐 ProPicks AI October update is out now! See which stocks made the listPick Stocks with AI

Employee of French drugmaker Ipsen to plead guilty to US insider trading

Published 09/10/2024, 05:55 PM
Updated 09/10/2024, 06:00 PM
© Reuters. FILE PHOTO: People exit the headquarters of the U.S. Securities and Exchange Commission (SEC) in Washington, D.C., U.S., May 12, 2021. REUTERS/Andrew Kelly/File Photo

By Nate Raymond

BOSTON (Reuters) -An employee of French drugmaker Ipsen has agreed to plead guilty to illegally making more than $262,000 by trading on inside information he learned about his company's plans to acquire cancer drug developer Epizyme (NASDAQ:EPZM) in 2022.

Dishant Gupta, Ipsen's director of data strategy and operations, plans to plead guilty to securities fraud and is settling related claims by the U.S. Securities and Exchange Commission, according to filings in Boston federal court on Tuesday.

A plea hearing is set for Oct. 8. Jeffrey Lichtman, a lawyer for the 40-year-old New Jersey resident, in an email said his client was working to resolve the case.

Ipsen said it does not comment on legal matters concerning current or former employees and was focused on compliance with applicable laws.

Prosecutors said that an Ipsen executive during a meeting in Cambridge, Massachusetts, in March 2022 asked Gupta to help him put together materials related to a potential acquisition of a cancer drug and an unidentified drug company's assets.

Days later, he met with Ipsen executives to discuss possible acquisitions in the oncology market, and by April 7, 2022, Gupta knew the cancer drug and assets Ipsen wanted to acquire belonged to Cambridge-based biotech Epizyme, the maker of the cancer medication Tazverik, prosecutors said.

That day, he began buying Epizyme shares in his wife's brokerage account, according to charging documents. He bought more in the days that followed as the companies discussed a potential outright acquisition of Epizyme, prosecutors said.

© Reuters. FILE PHOTO: People exit the headquarters of the U.S. Securities and Exchange Commission (SEC) in Washington, D.C., U.S., May 12, 2021. REUTERS/Andrew Kelly/File Photo

Gupta began conducting frequent internet searches that authorities said showed his awareness of a potential deal, with searches for "Epizyme buyout" and "Epizyme takeover," according to prosecutors and the SEC.

Ipsen announced its $247 million acquisition of Epizyme on June 27, 2022. Gupta then sold all of his Epizyme shares, netting him a profit of more than $262,000, prosecutors said.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.